A pharmaceutical company developing next-generation targeted protein degraders with an initial focus on tau-driven diseases like Alzheimer’s
4biocapital.comLondon, UKBiotech
4 sources · checked 1 time, last 27m ago
The 4BIO Capital release calls this a Series A, while Oyster’s Business Wire release calls it Series A-2; the company’s release wins. It names the same $60 million financing and lists both new and existing investors as participants.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A Series A-2 | $60M | 2026-11-10 | 4BIO Capital | 3 outlets. #23 in Trending |
4 sources · checked 1 time, last 27m ago [ VERIFIED · CORRECTED ] read against 3 of 4 sources The 4BIO Capital release calls this a Series A, while Oyster’s Business Wire release calls it Series A-2; the company’s release wins. It names the same $60 million financing and lists both new and existing investors as participants. | ||||